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Objective: Endovascular aortic repair (EVAR) for abdominal aortic aneurysm (AAA) is increasingly used for emergent
treatment of ruptured AAA (rAAA). We sought to compare the perioperative and long-term mortality, procedure-related
complications, and rates of reintervention of EVAR vs open aortic repair of rAAA in Medicare beneﬁciaries.
Methods: We examined perioperative and long-term mortality and complications after EVAR or open aortic repair per-
formed for rAAA in all traditional Medicare beneﬁciaries discharged from a United States hospital from 2001 to 2008.
Patients were matched by propensity score on baseline demographics, coexisting conditions, admission source, and
hospital volume of rAAA repair. Sensitivity analyses were performed to evaluate the effect of bias that might have resulted
from unmeasured confounders.
Results: Of 10,998 patients with repaired rAAA, 1126 underwent EVAR and 9872 underwent open repair. Propensity
score matching yielded 1099 patient pairs. The average age was 78 years, and 72.4% were male. Perioperative mortality
was 33.8% for EVAR and 47.7% for open repair (P < .001), and this difference persisted for >4 years. At 36 months,
EVAR patients had higher rates of AAA-related reinterventions than open repair patients (endovascular reintervention,
10.9% vs 1.5%; P < .001), whereas open patients had more laparotomy-related complications (incisional hernia repair,
1.8% vs 6.2%; P < .001; all surgical complications, 4.4% vs 9.1%; P < .001). Use of EVAR for rAAA increased from 6% of
cases in 2001 to 31% in 2008, whereas during the same interval, overall 30-day mortality for admission for rAAA,
regardless of treatment, decreased from 55.8% to 50.9%.
Conclusions: EVAR for rAAA is associated with lower perioperative and long-term mortality in Medicare beneﬁciaries.
Increasing adoption of EVAR for rAAA is associated with an overall decrease in mortality of patients hospitalized for
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://dx.doi.org/10.1016/j.jvs.2013.08.093Despite better preventive practices and increasing rates
of repair of intact abdominal aortic aneurysms (AAA) in
older and higher-risk populations,1 ruptured AAA (rAAA)
continues to cause >5000 deaths annually in the United
States.2,3 Autopsy data demonstrate that 50% to 70%
of patients with rAAA do not survive to hospital presenta-
tion.4 For those that do, the traditional treatment has been
emergent open aortic repair, but mortality after open aortic
repair remains >40%.5-7 For intact aneurysms, endovascu-
lar aortic repair (EVAR) offers improved perioperative
mortality and speedier recovery than open repair,8-10 and
EVAR has become the dominant treatment for intact
AAA repair in the U.S.11 Critically ill patients with rAAA
also may beneﬁt from EVAR, but necessary preoperative
imaging and speciﬁc anatomic requirements can make
EVAR less well suited for emergent use. As of 2008, only
31% of rAAA in the U.S. were treated with EVAR, whereas
>85% of intact repairs were treated with EVAR.1,12
Successful use of EVAR for rAAA was ﬁrst reported in
1994.13,14 Subsequent case series and observational studies
suggest that for selected patients, EVAR offers improved575
JOURNAL OF VASCULAR SURGERY
576 Edwards et al March 2014mortality compared with open repair.12,15-22 Conversely,
small randomized controlled trials demonstrated no differ-
ence in perioperative mortality,23,24 whereas other trials are
ongoing.25,26
More than 76% of rAAAs occur in those aged
>65 years enrolled in Medicare.4 Thus, experiences in
Medicare provide the most comprehensive data on rAAA
available. We sought to compare the perioperative and
long-term mortality and short-term and long-term compli-
cations in patients receiving EVAR vs open repair for rAAA
in the Medicare population. We also examined trends in
mortality for rAAA to estimate the overall effect of rising
adoption of EVAR on survival after rAAA.
METHODS
The study was approved by the Harvard Medical
School Institutional Review Board.
Patients. We identiﬁed all Medicare beneﬁciaries aged
$67 years who were admitted to a U.S. hospital with
a primary discharge diagnosis of rAAA (International Clas-
siﬁcation of Diseases, 9th Edition-Clinical Modiﬁcation
[ICD-9-CM] code 441.3) between 2001 and 2008. We
excluded patients with concurrent diagnoses of thoracic
aneurysm (441.1, 441.2), thoracoabdominal aneurysm
(441.6 or 441.7), and aortic dissection (441.00-441.03),
and those with procedural codes for repair of the thoracic
aorta (38.35, 38.45, 39.73) and visceral or renal bypass
(38.46, 39.24, 39.26).
To accurately identify rAAAs as distinct from intact
AAAs, we analyzed hospital and physician claims and only
included patients for whom the diagnosis was consistent in
both (Supplementary Fig 1, online only). Overall mortality
rates were consistent with those in published reports when
both the hospital and physician code were required to indi-
cate rupture. Treatment type was determined by examining
ICD-9 and Current Procedural Terminology (CPT) codes
(American Medical Association, Chicago, Ill) for open
surgical repair (ICD-9 38.44, 39.25, CPT 35081, 35082,
35102, 35103, 35646) and for endovascular repair (ICD-
9 39.71, CPT 34800, 34802, 34803, 34804, 34805).
When hospital and physician claims conﬂicted regarding
repair type (open vs endovascular), physician claims were
given priority.10 Patients who had EVAR and open repair
during the same hospitalization were classiﬁed as EVAR
patients who had conversion to open repair.
All patients had had at least 2 years of prior Medicare
experience, which we used to control for coexisting condi-
tions that might inﬂuence outcomes. We excluded beneﬁ-
ciaries enrolled in a Medicare Advantage health plan before
or during the index hospitalization.
Creating matched cohorts. To control for the
nonrandom assignment of patients to treatment groups,
we created matched cohorts of patients after estimating
logistic regression models predicting the likelihood of
EVAR (propensity score). As explanatory variables, we
used baseline demographic and coexisting conditions iden-
tiﬁed using inpatient and outpatient claims from the 2 years
before but not including the index hospitalization.10,27 Wealso included as covariates measures of hospital volume of
AAA repair, admission through the emergency department,
transfer from another hospital, and calendar year. We
matched each beneﬁciary who underwent EVAR with
one beneﬁciary who underwent open repair with the
closest estimated propensity to undergo EVAR. We chose
one-to-one matching, rather than many-to-one matching,
to maximize balance between treatment groups. To ensure
close matches, we required the estimated log-odds of
endovascular repair between a patient who underwent
endovascular repair and one who underwent open repair to
be within 0.60 standard deviations. This value removes
w90% of the bias in estimates of effects due to differences
in covariate distributions between treatment and compar-
ison groups.28
These methods, however, are not able to account for
the presence of unmeasured factors that might have inﬂu-
enced the treatment decision. For instance, if hemodynam-
ically unstable patients were preferentially treated with
open vs EVAR, our results could be biased in favor of
EVAR. To address this issue, we performed an additional
sensitivity analysis and an analysis of temporal trends in
repair type and mortality.
Mortality outcomes. Perioperative mortality was
deﬁned as death during the index hospitalization or
#30 days of the procedure. Long-term mortality
included all deaths during the entire follow-up period.
Dates of death were obtained from Medicare enrollment
data through December 13, 2010. Claims-based outcomes
were censored at December 31, 2008.
Perioperative outcomes and complications. Perio-
perative complications were assessed by examining diag-
nosis and procedure codes for the index hospitalization.
Complications of interest included conversion of EVAR
to open repair, reoperation for bleeding, tracheostomy,
embolectomy, wound dehiscence, mesenteric ischemia,
bowel resection, myocardial infarction, pneumonia, and
renal failure. We also examined length of stay of patients
who survived to hospital discharge and discharge disposi-
tion to home vs an institutional facility. A full listing of
diagnosis codes used to identify complications is included
in Supplementary Table II (online only).
Long-term complications. We identiﬁed subsequent
AAA-related hospitalizations with diagnosis and proce-
dure codes related to AAA, including open surgical rein-
teventions (open repair of the aneurysm, conversion from
endovascular to open repair, repair of a graft-enteric ﬁstula
or graft infection, axillobifemoral bypass), endovascular
reinterventions (repeat endovascular repair, stent graft
extension, embolization, aortic or iliac angioplasty, graft
thrombectomy), and laparotomy-related complications,
including nonsurgical bowel obstruction, surgical bowel
obstruction (obstruction-related lysis of adhesions or bowel
resection), and repair of an incisional hernia.
Statistical analysis. We compared the clinical charac-
teristics of the treatment cohorts using c2 tests for cate-
goric variables and t-tests for continuous variables other
than time-to-event variables. Survival time, freedom from
Table I. Patient characteristics
Variables
Unmatched Matched
EVAR (n ¼ 1126) Open (n ¼ 9872) P EVAR (n ¼ 1099) Open (n ¼ 1099) P
Demographics
Age, mean (SD) years 78.2 (6.6) 77.2 (6.3) <.001 78.2 (6.6) 78.2 (6.6) .75
Age, %
67-69 years 10.39 11.97 <.001 10.65 10.1 .98
70-74 years 23.18 25.32 23.29 22.84
75-79 years 27.35 31.98 27.48 27.48
80-84 years 21.31 16.68 21.11 22.11
$85 years 17.76 14.04 17.47 17.47
Male, % 74.2 74.2 .97 74.8 75.1 .88
Race, %
Black 6.3 3.8 <.001 6.1 6.6 .60
Other 3.1 2.0 .01 2.8 2.3 .42
Source of admission, %
Emergency department 63.2 80.5 <.001 64.2 63.4 .72
Outside hospital transfer 6.0 2.4 <.001 5.3 5.4 .92
Coexisting conditions, %
Myocardial infarction
In past 6 months 1.1 0.9 .66 0.9 0.9 1
In past 7-24 months 7.1 3.8 <.001 7.1 7.1 1
Congestive heart failure 19.0 12.2 <.001 18.4 16.7 .31
Cardiac arrhythmias 24.0 15.6 <.001 23.4 19.3 .02
Valvular disease 11.0 6.9 <.001 10.6 10.7 .94
Peripheral vascular disease 16.7 11.4 <.001 16.3 13.1 .04
Hypertension 61.1 54.4 <.001 60.7 60.2 .83
COPD 31.0 25.8 <.001 30.8 30.2 .78
Diabetes mellitus
Uncomplicated 16.2 11.8 <.001 15.6 15.8 .86
Complicated 3.9 2.2 <.001 3.6 2.6 .14
Renal disease 8.2 5.4 .02 8.2 8.7 .65
Metastatic cancer 2.7 0.9 <.001 2.6 1.8 .24
Solid tumor 16.0 11.9 <.001 15.9 15.3 .68
Obesity 2.0 1.6 .29 2.0 1.9 .88
ESRD 1.6 0.6 <.001 1.5 1 .33
Cerebrovascular disease 12.7 10.6 .03 12.4 12.0 .79
Intact AAA diagnosis 25.6 16.4 <.001 25.1 22.3 .12
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; EVAR, endovascular aortic repair; SD,
standard deviation.
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examined using Kaplan-Meier life-table methods. Differ-
ences between groups were tested with the log-rank test.
All analyses were performed in SAS 9.3 software (SAS
Institute, Cary, NC).
Temporal trends. To further explore if selection
contributed to differences in observed mortality for
EVAR vs open repair, we examined temporal trends in
overall repair rates and 30-day mortality of EVAR and
open repair. We used hospital claims to identify all hospi-
talizations with a discharge diagnosis code of
rAAA (441.3). EVAR patients were deﬁned as those
who had a concomitant code for an endovascular repair
(ICD-9-CM 38.44, 39.25), whereas open repair patients
were deﬁned as those who had a claim for open aortic
repair (ICD-9-CM 39.71, 39.90). Patients with a claim for
neither repair were considered to be unrepaired. If more
hemodynamically stable patients were offered EVAR, and
more unstable patients were preferentially offered open
repair as EVAR was adopted over time, we would expect tosee increasing 30-day mortality rates in those treated with
open repair.
Sensitivity analysis. To examine the effect of unmea-
sured confounders, we jointly modeled perioperative
mortality (conditional on EVAR) and treatment choice
(EVAR vs open repair) according to the methods described
by O’Malley et al.29 In this approach, any unmeasured
confounders are absorbed in the errors terms of the
patient’s underlying propensity to (1) undergo EVAR and
(2) suffer perioperative death. By examining the correlation
of the error terms in (1) and (2), we can estimate whether
a relationship exists between unmeasured factors that make
EVAR more likely and unmeasured factors that make
mortality more likely. More details on this approach and
the results of the sensitivity analysis can be found in the
Supplementary Statistical Analysis (online only).
RESULTS
We identiﬁed 10,998 patients who underwent repair
for rAAA from January 2001 to December 2008.
Table II. Perioperative outcomes
Outcome
EVAR
(n ¼ 1099)
Open
(n ¼ 1099) P
Perioperative mortality, %
All ages 33.8 47.7 <.001
67-69 years 18.8 38.7 <.001
70-74 years 27.7 41.0 <.001
75-79 years 30.1 43.0 <.001
80-84 years 39.2 53.5 <.001
$85 years 50.0 61.5 .02
Medical complications, %
Myocardial infarction 16.7 19.2 .13
Pneumonia 28.5 35.9 <.001
Acute renal failure 33.4 45.4 <.001
Hemodialysis 0.7 0.6 .80
Respiratory failure/
tracheostomy
4.6 9.9 <.001
Venous thromboembolism 8.0 6.8 .29
Surgical complications, %
Conversion to open repair 4.9
Reoperation for bleeding 2.3 3.0 .24
Embolectomy 3.6 6.4 .003
Wound dehiscence 2.5 4.6 .008
Operative site hematoma 8.0 4.5 <.001
Gastrointestinal bleeding 10.3 13.8 .01
Mesenteric ischemia 7.6 14.7 <.001
Bowel obstruction or ileus 12.7 17.0 .005
Colon resection 4.4 8.5 <.001
Ostomy 2.64 5.28 .002
Discharge to home, % 62.8 40.7 <.001
LOS of survivors to hospital
discharge, median (IQR) days
7 (4-24) 14 (9-23) <.001
EVAR, endovascular aortic repair; IQR, interquartile range; LOS, length of
stay.
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underwent EVAR. Baseline characteristics of the patients
and their coexisting conditions are listed in Table I. Before
matching, patients receiving EVAR tended to be older
(78.2 vs 77.2 years; P < .001), have more medical diag-
noses (eg, 19.0% with congestive heart failure vs 12.2%;
P < .001), and were more likely to have a pre-existing
diagnosis of AAA (25.6% vs 16.4%; P < .001). In con-
trast, patients receiving open repair were more likely to
have been admitted through the emergency department
(80.5% vs 63.2%; P < .001) and were less likely to have
been transferred from another hospital (2.4% vs 6.0%;
P < .001).
Propensity score matching yielded 1099 patient pairs.
With the exception of cardiac arrhythmias (16.3% vs
13.1%; P ¼ .02) and history of peripheral vascular disease
(16.3% vs 13.1%; P ¼ .04), there were no remaining statis-
tically signiﬁcant differences between the populations.
Perioperative outcomes. Perioperative outcomes are
summarized in Table II. Perioperative mortality was
33.8% for patients who underwent EVAR vs 47.7% for
patients who underwent open repair (P < .001). Patients
treated with EVAR experienced a lower rate of most
postoperative complications, including pneumonia (28.5%
vs 35.9% for open repair; P < .001), acute renal failure
(33.4% vs 45.4%; P < .001), respiratory failure requiring
tracheostomy (4.6% vs 9.9%; P < .001), and gastrointes-
tinal complications, including colon resection (4.4% vs
8.5%; P < .001) and mesenteric ischemia (7.6% vs 14.7%
P < .001). Several procedural complications also were less
common in EVAR than in open repair, including embo-
lectomy (3.6% vs 6.3%; P ¼ .003) and wound dehiscence
(2.5% vs 4.6%; P ¼ .008). In contrast, procedure-related
hematoma was more common in EVAR patients (8.0% vs
4.5%; P < .001), and conversion from EVAR to open
repair occurred in 4.9% of patients within the index
hospitalization or by 30 days.
Among patients who survived to discharge, the median
length of stay for patients undergoing EVAR was 7 days
(interquartile range, 4-24 days) compared with 14 days
(interquartile range, 9-23 days) for patients undergoing
open repair. Discharge was to home for 62.8% of EVAR
patients compared with 40.7% of patients who underwent
open repair (P < .001).
Late outcomes. Long-term survival for the entire
cohort and stratiﬁed by age is shown in Fig 1. EVAR was
associated with a survival beneﬁt that persisted for >4 years
after the intervention (P < .001) in all age groups.
Open surgical and endovascular AAA-related reinter-
ventions were more common after EVAR than after open
repair (Table III). Among EVAR patients, 1.9% underwent
open reintervention by 12 months and 3.9% by 36 months
vs 0.5% and 0.9% of open repair patients, respectively (P ¼
.002 by log-rank test). In addition, an endovascular reinter-
vention had occurred in 4.6% of EVAR patients by
12 months and in 10.9% by 36 months vs 0.6% and
1.5%, respectively, for patients who had open repair (P <
.001 by log-rank test).Laparotomy-related complications at 36 months were
more common in patients who had had open aortic repair,
including incisional hernia repair (6.2% vs 1.8% for EVAR;
P < .001), nonsurgical bowel obstruction (35.8% vs 18.7%
for EVAR), and any obstruction-related surgical interven-
tion (9.1% vs 4.4% for EVAR).
Trends in rAAA mortality. Trends of EVAR use and
30-day mortality by treatment type are presented in Fig 2.
Use of EVAR for rAAAs increased from 6% of repairs in
2001 (220 cases, 4.2% of total rAAA admissions) to 31% of
repairs in 2008 (828 cases, 20% of total rAAA admissions).
The number of untreated rAAAs remained nearly constant,
but the proportion of untreated rAAAs increased from 27%
in 2000 to 38.7% in 2004 and then decreased to 34.5% in
2008. Perioperative mortality for rAAA treated by EVAR
decreased from 46% in 2001 to 27% in 2008, and mortality
for rAAA treated by open repair decreased from 44.7% to
40%. The 30-day mortality of rAAA without treatment
remained w80%. Overall mortality for rAAA admissions,
whether treated or not, decreased from 55.8% to 50.9%
between 2001 and 2008.
Sensitivity analysis. As described in the
Supplementary Statistical Analysis (online only), our anal-
yses of unmeasured selection suggest that patients whose
unobserved factors make them more likely to be treated
with EVAR have a higher predicted mortality than other
Fig 1. Mortality of propensity-matched patients undergoing endovascular (Endo) and open repair of ruptured aortic
aneurysm (rAAA) is shown overall and stratiﬁed by age.
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that any unmeasured confounders were associated with an
underestimation rather than an overestimation of treat-
ment effect and would bias our ﬁndings against (rather
than for) EVAR (Supplementary Statistical Analysis, online
only).
DISCUSSION
In this comprehensive analysis of Medicare patients, we
found that EVAR of rAAA was associated with lower peri-
operative and long-term mortality, fewer in-hospital
complications, and shorter length of stay. The long-term
survival beneﬁt of EVAR persisted for >4 years. Consistent
with our prior work on intact AAA repair, patients under-
going EVAR had a higher likelihood of reintervention for
AAA, but this was balanced by lower rates of laparotomy-
related interventions. During this interval, overall mortality
of patients admitted to a hospital with an rAAA, regardless
of intervention, declined nearly 5%, whereas the proportion
of repairs performed using EVAR increased from 6% to 31%.
Because our study is observational, unmeasured selec-
tion remains of signiﬁcant concern. Most important, it ispossible that hemodynamically unstable patients are prefer-
entially offered open repair, which would result in higher
mortality for patients treated with open repair. We used
three approaches to mitigate this concern:
First, we created matched cohorts using propensity
score models that used all available patient factors,
including age, sex, race, ethnicity, coexisting conditions,
and hospital-level factors such as AAA repair volume.
Because patients transferred from other hospitals rather
than those admitted from the emergency department are
more likely to be hemodynamically stable and have a con-
tained rupture, we also included in our propensity model
an indicator variable for transfer from another hospital as
well as admission through the emergency department.
We observed that more patients who received EVAR had
a prior diagnosis of intact AAA, were less commonly
admitted through the emergency department, and were
more commonly transferred between hospitals before treat-
ment. In our ﬁnal propensity-matched analysis, these vari-
ables were well balanced between groups (Table I),
which should eliminate bias associated with these
conditions.
Table III. Late outcomes
Outcome
12 months 36 months
Pa
EVAR,
%
Open,
%
EVAR,
%
Open,
%
Reintervention
Open surgicalb 1.9 0.5 3.9 0.9 .002
Endovascularc 4.6 0.6 10.9 1.5 <.001
Laparotomy-related
complications
Bowel obstruction
Nonsurgical admissiond 7.3 15.4 18.7 35.8 <.001
Surgicale 0.7 1.8 2.5 3.0 .157
Incisional hernia 0.3 1.2 1.8 6.2 <.001
Any surgical interventionf 1.0 3.0 4.4 9.1 <.001
EVAR, Endovascular aortic repair.
aLate outcomes were analyzed using survival analysis, and P values are those
generated by the log-rank test.
bConversion to open repair, open aneurysm repair, aortobifemoral bypass,
axillofemoral or axillobifemoral bypass, repair of infected graft or graft-
enteric ﬁstula, thrombectomy, femoral-femoral bypass.
cRepeat EVAR, embolization, angioplasty (aortic or iliac), extension cuff.
dHospital admission with diagnosis of bowel obstruction without lysis of
adhesions or bowel resection.
eLysis of adhesions or bowel resection performed for diagnosis of
obstruction.
fSurgical intervention for bowel obstruction or incisional hernia.
A
B
Fig 2. Trends in ruptured abdominal aortic aneurysm (rAAA)
treatment and 30-day mortality by treatment type from 2001 to
2008. A, Proportion of rAAA admissions by treatment type. B,
30-day mortality of admission for rAAA by treatment type.
EVAR, Endovascular aortic repair.
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taneously modeled the selection effect and outcomes.29
The results of this sensitivity analysis suggest that unob-
served features that make EVAR more likely are modestly
associated with higher mortality. Hence, this suggests
that sicker patients may be selected for EVAR, thus biasing
our results in favor of open repair.
Finally, we examined overall trends in rupture repair
and mortality. In the decades preceding the introduction
of EVAR, the rate of repair and mortality associated with
rAAA repair was stable.6 Since the introduction of
EVAR, however, overall mortality for rAAA hospitaliza-
tions, with or without treatment, has decreased.1 During
the same period, the proportion of rAAA repairs performed
by EVAR increased, whereas the mortality for EVAR and
open repair for rAAA decreased. If improved mortality in
EVAR patients were due to selection of healthier patients,
we would expect to see an increase in mortality for patients
undergoing open repair as EVAR was adopted. Instead, we
see a decrease in mortality with open rAAA repair, consis-
tent with sicker patients being offered EVAR. This ﬁnding
contrasts with previous work where we showed that
mortality after open intact AAA repair remained stable
during this same interval.10 Thus, it is unlikely that our
results could be explained by more unstable patients being
preferentially treated with open repair rather than with
EVAR.
We also examined trends in unrepaired rAAAs. The
improved outcomes with EVAR and open repair over
time could be explained by an increasing proportion of
patients being turned down for surgical intervention.
Although we saw an increase in the proportion ofunrepaired cases of all rAAA admissions with a concomitant
decrease in the proportion of open repairs from 2001 to
2003 (Fig 2), this trend reversed after 2003, and a steady
decline occurred in the percentage of unrepaired rAAAs.
Also during this period, the proportion of EVAR increased,
and the proportion of open repair continued to decline.
Hence the observed improved mortality for all ruptures,
regardless of treatment, may be driven by improved
outcomes in EVAR vs open repair and by the adoption
of EVAR being associated with an increasing proportion
of patients with rAAA receiving any treatment.
Our results also are consistent with clinical reports of
the use of EVAR for rupture patients. Some centers
perform EVAR on patients in shock without preoperative
imaging17 and have optimized protocols to expedite the
use of EVAR in critically ill patients18,19 Some have also
argued that EVAR may be of most beneﬁt to the most crit-
ically ill because they are least likely to survive an open
procedure.30 These authors describe a protocol of rapid
transport to the operating room with percutaneous femoral
access with an awake patient through which an aortic
occlusion balloon may be inserted for rapid supraceliac
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ing the commonly observed loss of hemodynamic stability
associated with the release of the hemoperitoneum. At this
point, the surgeon may proceed with EVAR if appropriate
or open repair if EVAR is not possible based on anatomy.
The adoption of such protocols and the multispecialty
coordination and training may also help improve mortality
with open repair as well.
One surprising ﬁnding is that in our cohort, patients
with unrepaired rAAA had a 30-day mortality of w80%,
in contrast to previous ﬁndings that >98% of patients
with unrepaired rAAA die #30 days.31 There are several
possible explanations for this. One possibility is that some
patients are coded as rAAA as a “rule out” diagnosis and
that they do not actually have an rAAA. Another possibility
is that some “unoperated-on” patients identiﬁed using
hospital claims for our trends analysis received repair but
were not correctly coded. Importantly for our analysis,
we have no reason to suspect that coding practices changed
over time, and hence, our analyses of trends in repair type
and mortality should be unaffected. Given the concern of
diagnostic accuracy of hospital claims alone, for our
primary analysis of mortality, early and late complications
of EVAR and open repair, we used both physician and
hospital claims to ensure a more homogenous cohort of
rAAA patients (Supplementary Fig 1, online only).
Although our ﬁndings are consistent with prior studies
of rAAA in Medicare patients,20 our results extend earlier
work in several ways:
First, we include more recent data, with procedures
performed up to 2008. The period 2005 to 2008 demon-
strated the fastest growth of EVAR for rAAA, and these
more recent data better reﬂect current approaches.
Second, we report rates of perioperative and postoper-
ative complications, rates of reintervention, discharge
disposition, and length of stay, which have not been re-
ported in the Medicare population.
Third, we incorporate longer-term data on outcomes
and show that the beneﬁts of EVAR are durable for
>4 years. This is longer than has been seen in trials for
EVAR for intact AAA, which may indicate a larger survival
advantage for rAAA than for intact AAA using endovascu-
lar approaches.
Fourth, our approach incorporates physician diagnoses
in addition to hospital discharge data. When hospital
coding is compared with physician coding, we ﬁnd signiﬁ-
cant discrepancies (Supplementary Fig 1, online only), sug-
gesting substantial potential for misclassiﬁcation of intact
AAAs as rAAAs. Although our approach likely excluded
some true rupture cases from our analyses, by requiring
consistent coding of rAAA across physician and hospital
claims, we generated a cohort that is likely less contami-
nated by these incorrectly coded cases. Because 80% of
intact AAAs are now repaired using EVAR and given the
substantially lower perioperative mortality seen with
EVAR for intact AAA, inappropriately including intact
AAAs in our cohort likely would bias our results in favor
of EVAR. Our approach attempted to minimize thelikelihood of this occurrence by using the strictest criteria
possible to identify cases of rAAA from the administrative
data.
Our results are in contrast to two randomized
controlled trials that showed no mortality beneﬁt for
EVAR vs open repair for rAAA.23,24 In general, these trials
were small (<150 patients) and, hence, had limited power
to detect the mortality differences seen in our work and less
power to detect the early and late complications we report.
These trials also required preoperative imaging to assess
eligibility for EVAR, thus excluding patients too unstable
to undergo a computed tomography scan and limiting
generalizability of their results. Larger, more inclusive clin-
ical trials are ongoing.25
Our work has several limitations. Administrative data
are subject to coding errors and variability, and the lack
of clinical data made it impossible to validate the coding
of rAAA using other sources such as imaging results.
We did make efforts to minimize errors in the initial diag-
nosis by requiring consistent physician and hospital
claims, although this did exclude many potential cases
(Supplementary Fig 1, online only). We also did not have
data regarding aneurysm anatomy, which is important in
determining whether a patient can receive EVAR, but we
attempted to account for this by eliminating patients with
renal or visceral bypass or involvement of the thoracic
aorta.
CONCLUSIONS
EVAR is associated with improved perioperative and
long-term mortality for rAAA, shorter length of stay, and
decreased laparotomy-related complications. The use of
EVAR for rAAA increased from 2001 to 2008, and the
overall mortality for patients hospitalized for rAAA
decreased from 55.8% to 50.9%. As centers continue to
adopt EVAR and current centers reﬁne protocols for its
emergent use for rAAA, there will be further opportunities
to study the effects of EVAR on rAAA outcomes.
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Our primary sensitivity analysis was designed to test for
the extent to which unmeasured differences in health status
might be biasing our results. Although propensity score
methods account for confounding by observed predictors,
they offer no reassurance against unobserved confounders.
One approach to account for unmeasured confounding is
to jointly model perioperative mortality conditional on
endovascular aortic repair (EVAR) and use of EVAR vs
open repair. Because perioperative mortality and EVAR
are dichotomous variables, the bivariate probit model1-5
may be used to account for unmeasured confounding while
modeling the effects of treatment (EVAR vs open) and
other observed predictors of perioperative mortality.
This model is deﬁned by a simultaneous equation
system, wherein an equation for treatment selection is
linked to an equation for the outcome from treatment
through their shared dependence on unmeasured variables.
The direction and magnitude of the net effect of the
unmeasured confounders is quantiﬁed by the extent to
which the relationship between perioperative mortality
and EVAR deviates from that predicted based on the
observed predictors. The size and magnitude of this devia-
tion is quantiﬁed in terms of a correlation coefﬁcient. The
further the correlation is from 0, the more that unmeasured
selection effects are expected to yield biased estimates
under a propensity score or other method reliant on the
nonexistence of unmeasured confounders. For a complete
description of the bivariate probit model in the context
of a comparison between EVAR and open repair, please
refer to O’Malley et al.6
The results of the bivariate probit analysis are presented
in Table A; estimates (together with t values and P values)
for the equation predicting the likelihood of perioperative
mortality are presented in the ﬁrst three columns to the
right of the list of predictors, whereas those for the equa-
tion predicting the likelihood of undergoing endovascular
surgery are presented in the right-most three columns.
Those predictors that are particular to a given model (eg,
the effect of EVAR on mortality) only have estimates for
that model.
The effect of EVAR (the effect of primary interest)
is signiﬁcant and negative (e0.630; P ¼ .0292) implying
that the risk of perioperative mortality is lower for EVARthan for open, all else equal. Secondly, the selection
effect correlation parameter is estimated to be 0.093 (P ¼
.250), suggesting that individuals who are more likely to
receive EVAR in unmeasured ways are more likely to suffer
perioperative mortality. Therefore, the propensity score
analysis that does not adjust for unmeasured confounding
is more likely biased against ﬁnding a signiﬁcant effect (as
EVAR patients essentially have unmeasured risk factors
that place them at greater risk for perioperative mortality)
than ﬁnding a signiﬁcant effect when none exists.
Owing to the relative scarcity of EVAR observations,
effects estimated for it are less precise than those for
open. For example, the effect of institutional EVAR
volume has a larger negative coefﬁcient than that for insti-
tutional open volume 0.170 vs 0.042 but is less signif-
icant (P ¼ .227 vs .011). Both volume effects are consistent
with past ﬁndings that the risk of perioperative mortality is
lower at institutions with higher annual volumes of the
same procedures. Further face validity in the bivariate
probit model is seen from the fact that perioperative
mortality is much higher for urgent cases (0.088; P ¼
.004) and that the relative use of EVAR has increased
rapidly over time (effect of 0.008 per day; P < .0001).
The coherency of these ﬁndings with past observations by
others offers further evidence that the estimated effects
under this model are reliable.REFERENCES
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Table A. Parameter estimates of regression coefﬁcients for bivariate probit model adjusting for clinical and nonclinical
adjusters, reason, and source of admission, and institutional volume for the same procedure that was performed on the
patient.
Term
Perioperative equation Endovascular equation
Estimate t value P value Estimate t value P value
Key predictors
Endovascular repair 0.630 2.18 .0292
Proportion endo 2.064 21.040 <.0001
BC(total volume)# 0.058 1.890 .059
l(total volume) 0.352 2.560 .010
BC(endo volume, endo pats)# 0.170 1.210 .227
BC(open volume, open pats)# 0.042 2.540 .011
l(endo volume, endo pats) 0.294 0.680 .493
l(open volume, open pats) 0.274 1.870 .061
Nonclinical adjusters
Procedure date 0.008 10.040 <.0001
Procedure date (endo pats) 0.002 1.210 .227
Procedure date (open pats) 0.001 1.470 .142
Urgent admission 0.088 2.910 .004 0.331 8.020 <.0001
Transfer 0.062 0.870 .384 0.259 2.860 .004
Patient characteristics
Intercept 0.066 1.220 .224 3.132 24.860 <.0001
Age 70-74 (baseline 67-69) 0.158 4.340 <.0001 0.029 0.490 .625
Age 75-79 (baseline 67-69) 0.509 12.730 <.0001 0.185 2.900 .004
Age 80 & over (baseline 67-69) 0.766 10.300 <.0001 0.369 3.530 .000
Male 0.124 4.660 <.0001 0.100 2.350 .019
Black 0.299 4.990 <.0001 0.291 3.510 .000
ESRD 0.342 2.680 .007 0.254 1.540 .123
Chronic renal insufﬁciency 0.203 3.740 .000 0.059 0.760 .446
CABG 0.378 3.360 .001 0.352 1.500 .132
PCI 0.254 2.540 .011 0.127 0.980 .328
CAD without procedure 0.038 1.050 .296 0.153 3.000 .003
CHF 0.155 4.020 <.0001 0.173 3.090 .002
COPD 0.076 2.760 .006 0.044 1.030 .302
Vascular disease 0.102 3.250 .001 0.028 0.580 .564
Prior AAA diagnosis 0.002 0.070 .942 0.117 2.400 .016
AAA, Abdominal aortic aneurysm; CABG, coronary bypass surgery; CAD, coronary artery disease; CHF, chronic heart failure; COPD, chronic obstructive
pulmonary disease; ESRD, end-stage renal disease; PCI, percutaneous coronary intervention.
The estimated selection effect (correlation between the unmeasured latent variables affecting perioperative mortality and likelihood of receiving EVAR) is
0.093 (t ¼ 1.15; P ¼ .250). #The Box-Cox transformation7 with parameter l of x is given by x (l) ¼ (xl e 1)/l if l s 0 or otherwise x (l) ¼ log (x).
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Supplementary Fig 1 (online only). Cohort formation and determination of treatment type. EVAR, Endovascular
aortic repair; HMO, health maintenance organization.
Supplementary Fig 2 (online only). Mortality of unmatched patients undergoing endovascular (Endo) and open
repair of ruptured aortic aneurysm (rAAA) is shown overall and stratiﬁed by age.
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Supplementary Table I (online only). Physician and hospital coding of ruptured (rAAA) and intact abdominal aortic
aneurysm (AAA) from 2005 to 2008
Hospital diagnosis Physician diagnosis No. 30-day mortality, % Open repairs, % Open repairs coded as ruptures, %
Rupture Intact 190 20 62 19
Intact Rupture 2519 7 47 15
Rupture Rupture 5351 45 82 87
Patients with consistent coding for rAAA in hospital and physician codes have a substantially higher 30-day mortality of 45%, which is consistent with prior
reports regarding mortality of rAAA. Also, a substantially higher proportion of repairs were performed as open repairs (82%), which is also consistent with prior
reports regarding trends in rAAA repair. Because separate codes exist for open repair of rAAA vs open repair of intact AAA, we examined the percentage of
open rAAA repairs that had the procedure code for rupture repair. Among patients with consistent rupture diagnosis, 87% of open repairs were coded as
rupture repairs, whereas 15% to 19% of patients with inconsistent codes were coded as rupture repairs. Taken together, it appears that patients with inconsistent
coding often have intact AAA, as EVAR is the dominant treatment for intact AAA, and the mortality is much lower than for rAAA, and their inclusion into the
cohort would bias the results to suggest a survival beneﬁt for EVAR.
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Supplementary Table II (online only). Outcome deﬁnitions
Outcomes Complication
Perioperative outcomes
Medical complications
410.00 Acute myocardial infarctiona
481.00, 482.00 Pneumoniaa
584.5, 584.9, 584.0 Acute renal failurea
90935, 90937, 90940, 36800, 36810, 36815,
36818, 36819, 36820, 36821, 36825, 36830,
36831, 36832, 36833, 36834
Hemodialysisb
415.1, 453.4 Venous thromboembolisma
Surgical complications
34830, 34831, 34832 Conversion to openb
35860, 35840 Reoperation for bleedingb
31603, 31605, 31600 Tracheostomyb
34201, 34203 Embolectomyb
97602, 97597, 97598 Wound dehiscenceb
99812 Hematomab
578 Gastrointestinal bleedinga
55700, 55790 Mesenteric ischemiab
560 Bowel obstruction (intestinal obstruction without mention of hernia)a
44140, 44141, 44143, 44144, 44145, 44146,
44147, 44150, 44151, 44155, 44160, 44204,
44205, 44206, 44207, 44208, 44210, 44211,
44212, 44213, 44110
Colon resectionb
Late outcomes
Open surgical reinterventionb
34830, 34831, 34832 Conversion to open repair
35082, 35082,35092,35103 Open AAA repair
35907, 35870 Graft infection
35654, 35621 Aortobifemoral, axillofemoral or axillobifemoral bypass
35875, 35876 Thrombectomy
35131, 35132 Iliac aneurysm repair
35661 Femoral-femoral bypass
Endovascular reinterventionb
34800, 34802, 34803, 34804, 34805, 0078T,
0080T, 0001T, 0002T
Endovascular AAA repair (redo)
35472, 35473, Angioplasty
34825, 34826 Cuff extension
37204 Embolization
34900, 75954 Endovascular iliac aneurysm repair
Laparotomy-related complications
Bowel obstruction (nonsurgical admission)a
560.1 Paralytic ileus
560.8 Intestinal obstruction without mention of hernia
560.81 Intestinal or peritoneal adhesions with obstruction
560.89 Pseudo-obstruction or mural thickening causing obstruction
560.9 Unspeciﬁed intestinal obstruction
552.21 Incisional hernia with obstruction
Bowel obstruction (surgical)b
44005 Enterolysis (freeing of intestinal adhesion)
44180 Laparoscopy, surgical, enterolysis (freeing of intestinal adhesion)
44202 Laparoscopy, surgical; enterectomy; resection of small intestine
44203 .each additional small intestine resection
44120 Enterectomy, resection of small intestine; single resection
44130 Enteroenterostomy, anastomosis of intestine
44186 Laparoscopy, surgical; jejunostomy (eg, for decompression or feeding)
44187 .ileostomy or jejunostomy, nontube
44140 Colectomy, partial; with anastomosis
44141 .with skin level cecostomy or colostomy
44143 .with end colostomy and closure of distal segment
44144 .with resection, with colostomy or ileostomy and creation of mucoﬁstula
44160 Colectomy, partial, with removal of terminal ileum with ileocolostomy
44204 Laparoscopy, surgical; colectomy, partial, with anastomosis
44205 .with removal of terminal ileum with ileocolostomy
44206 .with end colostomy and closure of distal segment
44213 Laparoscopy, surgical; mobilization of splenic ﬂexure with partial colectomy
(Continued on next page)
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Supplementary Table II (online only). Continued.
Outcomes Complication
44188 Laparoscopy, surgical, colostomy or skin level cecostomy
Incisional herniab
49560 Repair initial incisional or ventral hernia; reducible
49561 .incarcerated or strangulated
49565 Repair recurrent incisional or ventral hernia; reducible
49566 .incarcerated or strangulated
49568 Implantation of mesh for incisional or ventral hernia
49654 Laparoscopy, surgical, repair, incisional hernia; reducible
49655 .incarcerated or strangulated
49656 Laparoscopy, surgical, repair, recurrent incisional hernia; reducible
49657 .incarcerated or strangulated
AAA, Abdominal aortic aneurysm.
aInternational Classiﬁcation of Diseases-9th edition (ICD-9) codes.
bCurrent Procedural Terminology (CPT) codes.
Supplementary Table III (online only). Perioperative
outcomes in unmatched sample, by treatment
Outcome
EVAR
(n ¼ 1126)
Open
(n ¼ 9872) P
Perioperative mortality, %
All ages 33.8 50.2 <.0001
67-69 years 18.8 39.6 <.0001
70-74 years 27.6 42.2 <.0001
75-79 years 30.2 49.2 <.0001
80-84 years 38.8 58.0 <.0001
$85 years 50.5 67.0 <.0001
Medical complications, %
Myocardial infarction 16.9 15.7 .3199
Pneumonia 28.7 31.7 .0405
Acute renal failure 33.7 39.4 .0002
Hemodialysis 0.7 0.6 .7956
Respiratory failure/
tracheostomy
4.5 8.5 <.0001
Venous thromboembolism 8.1 4.4 <.0001
Surgical complications, %
Conversion to open repair 4.8
Reoperation for bleeding 2.3 2.5 .7082
Embolectomy 3.6 6.6 <.0001
Wound dehiscence 2.5 3.8 .0285
Operative site hematoma 8.2 3.9 <.0001
Gastrointestinal bleeding 10.4 11.2 .4169
Mesenteric ischemia 6.4 7.5 .192
Bowel obstruction or ileus 13.1 15.7 .0182
Colon resection 4.4 6.7 <.0001
Ostomy 2.8 4.2 .018
Discharge to home, % 62.3 45.3 <.0001
Length of stay, median
(IQR) days
7 (4-13) 13 (9-21) <.0001
EVAR, Endovascular aortic repair; IQR, interquartile range.
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